Preliminary Results from a European Post Authorization Study to Assess the Safety of Paxlovid among Patients with Moderate or Severe Hepatic or Renal Impairment

Authors
Category Primary study
Conference41st International Society for Pharmacoepidemiology International Conference, ISPEs 2025
Year 2025
This article has no abstract
Epistemonikos ID: eac0440e3f9ca6099eca3fc046fc74a80433b1d9
First added on: Jan 06, 2026